OMER
resolvedOmeros Corporation
Price Chart
Gap Information
Score Analysis
Model 1: Rerate Score
Model 2: Trade Probability
AI Thesis
Omeros Corporation's 23% gap up signals a potentially transformative catalyst that Wall Street views as fundamentally altering the company's risk/reward profile. As a clinical-stage biopharmaceutical company with OMIDRIA (phenylephrine/ketorolac injection for cataract surgery) as its commercial product and a deep pipeline centered around narsoplimab (MASP-2 inhibitor) and other complement-targeting assets, Omeros has historically traded at depressed levels due to reimbursement uncertainty, FDA setbacks on narsoplimab, and cash runway concerns. A gap of this magnitude likely reflects a binary positive outcome—potentially related to regulatory progress, OMIDRIA reimbursement clarity, settlement of legal disputes, or a strategic partnership—that materially de-risks the investment thesis. The rerating probability is meaningfully elevated because biotech gaps of this size typically reflect genuine fundamental repricing rather than speculative noise. With the stock trading well above its 50-day SMA ($10.76) and its prior close, momentum and short-covering dynamics could amplify the move. However, Omeros's history of volatility—including sharp reversals after initial enthusiasm—means sustaining this gap requires conviction that the catalyst translates into durable value creation, whether through revenue acceleration, pipeline advancement, or balance sheet stabilization.
Analyzed by rerate-v2+glm-5.2 · Aug 13, 2026
Catalysts
- FDA regulatory progress or pathway clarification for narsoplimab in HSCT-TMA or IgA nephropathy
- OMIDRIA reimbursement stabilization or favorable CMS/contracting developments
- Resolution of legal proceedings including securities litigation or patent disputes
- Strategic partnership, licensing deal, or milestone payment unlocking pipeline value
- Positive clinical data readout from complement or GPCR platform programs
- Potential cash infusion or financing improvement extending runway
Risks
- Narsoplimab has previously received FDA Complete Response Letters; regulatory uncertainty persists
- Cash burn and capital raising dilution risk remain significant given clinical-stage pipeline
- OMIDRIA faces generic competition risk and reimbursement pressure
- Small-cap biotech volatility; gap could fade if catalyst details underwhelm on conference call
- Limited revenue base makes stock highly sensitive to binary outcomes
- No clear 200-SMA reference suggests stock has been in extended downtrend; overhead supply likely
Technical Setup
Forward Returns
Outcomes calculated Aug 21, 2026
Post-Gap Validation — 5-Day Follow-Through
Day-by-Day Price Action
| Day | Close | High | Low | Volume |
|---|---|---|---|---|
| Day 1 | $17.19 | $17.61 | $16.54 | 3.68M |
| Day 2 | $17.36 | $17.52 | $16.90 | 2.47M |
| Day 3 | $17.19 | $17.29 | $16.90 | 1.23M |
| Day 4 | $18.39 | $18.89 | $17.13 | 3.20M |
| 📍 Day 5 | $18.63 | $18.73 | $18.07 | 1.65M |
Signal Breakdown
Gap held — only 1% erased, price maintained gains
Moderate volume decline (55%)
Higher highs with peak close on day 5 — continued buying interest
Moderate drawdown (3.9%)
No fundamental data to evaluate beat quality
Analysis updated Aug 21, 2026